

115TH CONGRESS  
1ST SESSION

**H. R.** \_\_\_\_\_

To amend the Federal Food, Drug, and Cosmetic Act to prohibit the dissemination of a direct-to-consumer advertisement for any opioid, and for other purposes.

---

IN THE HOUSE OF REPRESENTATIVES

Mr. NOLAN introduced the following bill; which was referred to the Committee on \_\_\_\_\_

---

**A BILL**

To amend the Federal Food, Drug, and Cosmetic Act to prohibit the dissemination of a direct-to-consumer advertisement for any opioid, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Opioid Advertising and  
5 Prescriber Prohibition Act of 2018”.

1 **SEC. 2. PROHIBITION AGAINST DIRECT-TO-CONSUMER AD-**  
2 **VERTISING FOR OPIOIDS.**

3 (a) PROHIBITION.—Section 301 of the Federal Food,  
4 Drug, and Cosmetic Act (21 U.S.C. 331) is amended by  
5 adding at the end the following:

6 “(eee) The dissemination of a direct-to-consumer ad-  
7 vertisement for any opioid (as defined in section 102 of  
8 the Controlled Substances Act).

9 “(fff) The dissemination of a direct-to-consumer ad-  
10 vertisement for any opioid (as defined in section 102 of  
11 the Controlled Substances Act) receptor antagonist or  
12 other opioid-related drug therapy (as defined by the Sec-  
13 retary) except that this paragraph does not apply with re-  
14 spect to any advertisement by a State, local, or tribal gov-  
15 ernment.

16 “(ggg) The promotion of any opioid (as defined in  
17 section 102 of the Controlled Substances Act), opioid (as  
18 so defined) receptor antagonist, or other opioid-related  
19 drug therapy (as defined by the Secretary)—

20 “(1) by any person engaged in the development  
21 or sale of any such opioid, opioid receptor antago-  
22 nist, or therapy; and

23 “(2) to a health care provider that is registered  
24 under the Controlled Substances Act to prescribe  
25 any such opioid, opioid receptor antagonist, or ther-  
26 apy.”.

1           (b) APPLICABILITY.—Paragraphs (eee), (fff), and  
2 (ggg) of section 301 of the Federal Food, Drug, and Cos-  
3 metic Act (21 U.S.C. 331), as added by subsection (a),  
4 apply beginning on the date that is 90 days after the date  
5 of enactment of this Act.